Targeting integrins α4β7 and αEβ7 with etrolizumab could have potential as a treatment for ulcerative colitis. In a phase II study in patients with moderately-to-severely active ulcerative colitis, 21% of patients in the etrolizumab 100 mg group and 10% of patients in the 300 mg etrolizumab group achieved clinical remission at week 10. Clinical remission was not achieved by any patient in the placebo group. Phase III studies have now been planned.
References
Vermeire, S. et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 10.1016/S1040-6736(14)60661-9
Rights and permissions
About this article
Cite this article
Phase II study reveals potential of etrolizumab as induction therapy for ulcerative colitis. Nat Rev Gastroenterol Hepatol 11, 395 (2014). https://doi.org/10.1038/nrgastro.2014.105
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2014.105
